X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will advance the development of DYNE-101, which is an antisense oligonucleotide. Currently, it is being evaluated in the early-stage trials for the treatment of myotonic dystrophy.
Lead Product(s): DYNE-101
Therapeutic Area: Genetic Disease Product Name: DYNE-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $374.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 28, 2024
Details:
The net proceeds will be used in the clinical development of the lead product DYNE-101, which is an antisense oligonucleotide. Currently, it is being evaluated in the early-stage clinical trial studies for the treatment of myotonic dystrophy.
Lead Product(s): DYNE-101
Therapeutic Area: Genetic Disease Product Name: DYNE-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $325.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 21, 2024
Details:
The proceeds will be used in the development of the DYNE-101, an antisense oligonucleotide. It is being evaluated in the early-stage clinical trial studies for the treatment of myotonic dystrophy.
Lead Product(s): DYNE-101
Therapeutic Area: Genetic Disease Product Name: DYNE-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering May 20, 2024
Details:
DYNE-101 is an investigational therapeutic which consists of an antisense oligonucleotide conjugated to a Fab that binds to the TfR1. It is being evaluated in the Phase 1/2 for people living with DM1.
Lead Product(s): DYNE-101
Therapeutic Area: Genetic Disease Product Name: DYNE-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2024
Details:
The Company intends to use the proceeds to fund the ongoing clinical development of DYNE-101, an experimental treatment for Duchenne muscular dystrophy and DYNE-251, including the acceleration of activities related to expedited regulatory pathways for DYNE-101 and DYNE-251.
Lead Product(s): DYNE-101
Therapeutic Area: Genetic Disease Product Name: DYNE-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $345.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 11, 2024
Details:
The Company intends to use the proceeds to fund the ongoing clinical development of DYNE-101, an experimental treatment for Duchenne muscular dystrophy and DYNE-251, including the acceleration of activities related to expedited regulatory pathways for DYNE-101 and DYNE-251.
Lead Product(s): DYNE-101
Therapeutic Area: Genetic Disease Product Name: DYNE-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering January 03, 2024
Details:
DYNE-101 is an investigational therapeutic which consists of an antisense oligonucleotide conjugated to a fragment antibody (Fab) that binds to the transferrin receptor 1 (TfR1). It is being evaluated in the Phase 1/2 global clinical trial for people living with DM1.
Lead Product(s): DYNE-101
Therapeutic Area: Genetic Disease Product Name: DYNE-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
DYNE-101 is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE clinical trial for people living with myotonic dystrophy type 1 (DM1).
Lead Product(s): DYNE-101
Therapeutic Area: Genetic Disease Product Name: DYNE-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Details:
DYNE-101 consists of an antigen-binding Fab conjugated to an ASO and is designed to enable targeted muscle tissue delivery with the goal of reducing toxic DMPK RNA in the nucleus.
Lead Product(s): DYNE-101
Therapeutic Area: Genetic Disease Product Name: DYNE-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
DYNE-251 consists of a phosphorodiamidate morpholino oligomer conjugated to a fragment antibody that binds to the TfR1, allowing muscle cells to create functional dystrophin protein. It is being evaluated for duchenne muscular dystrophy who are amenable to exon 51 skipping.
Lead Product(s): DYNE-251
Therapeutic Area: Genetic Disease Product Name: DYNE-251
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
